• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ALXO

    ALX Oncology Holdings Inc.

    Subscribe to $ALXO
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: alxoncology.com

    Peers

    $ZYME

    Recent Analyst Ratings for ALX Oncology Holdings Inc.

    DatePrice TargetRatingAnalyst
    3/6/2025$2.00 → $3.00Hold → Buy
    Jefferies
    12/19/2024$12.00 → $2.00Buy → Hold
    Jefferies
    3/8/2024$10.00 → $14.00Buy → Hold
    Stifel
    12/8/2023$8.00 → $18.00Hold → Buy
    Jefferies
    3/1/2022$60.00 → $36.00Buy
    Stifel
    12/22/2021$65.00 → $25.00Buy → Hold
    Jefferies
    9/30/2021$106.00Buy
    Stifel
    See more ratings

    ALX Oncology Holdings Inc. SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

      SCHEDULE 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      5/15/25 4:15:24 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

      SCHEDULE 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      5/15/25 4:05:22 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by ALX Oncology Holdings Inc.

      10-Q - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

      5/8/25 4:01:21 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

      5/8/25 8:35:07 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

      4/25/25 4:01:07 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by ALX Oncology Holdings Inc.

      EFFECT - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

      4/25/25 12:15:18 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by ALX Oncology Holdings Inc.

      DEF 14A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

      4/21/25 4:10:02 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by ALX Oncology Holdings Inc.

      S-3 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

      3/6/25 5:26:32 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by ALX Oncology Holdings Inc.

      10-K - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

      3/6/25 4:33:54 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

      3/6/25 4:01:08 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ALX Oncology Holdings Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more

    ALX Oncology Holdings Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that management will participate in the Jefferies 2025 Global Healthcare Conference. Details are as follows: Format: Fireside Chat Date: Thursday, June 5, 2025Time: 1:25 PM ETLocation: New York, NYWebcast link: Available here The live webcast of the Jefferies fireside chat can be accessed by visiting the Investors section of ALX Oncology's website at www.alxoncology.com under the Events section of the Even

      5/30/25 8:00:21 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

      - A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity - Following recent IND clearance from U.S. FDA, ALX2004 will enter clinical studies mid-year 2025 with initial safety data anticipated in 1H 2026 - Trials evaluating the Company's lead investigational therapy, CD47-blocker evorpacept, in breast and colorectal cancers planned to initiate in mid-2025 with multiple key inflection points from evorpacept and ALX2004 development programs anticipated in 2026 SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSW

      5/20/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

      SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company's potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for ALX2004 following clearance of the Investigational New Drug application from the U.S. Food and Drug Administration e

      5/13/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company to host webcast focused on ALX2004 research program on May 20Company will not pursue U.S. registrational path in gastric cancer following receipt of FDA feedback that accelerated approval pathway is not feasible based on ASPEN-06 due to standard-of-care evolving to ENHERTU®Data milestones expected acros

      5/8/25 8:30:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

      SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX OncologyALX Oncology (NASDAQ:ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives. ALX Oncology's lea

      5/2/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

      - Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity - Combination generated complete responses (CR) in 83% of patients with indolent relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) comparing favorably to 34% historical CR rate with R2 alone - Phase 2 portion of trial in patients with previously untreated indolent NHL (iNHL) is ongoing and has completed enrollment SOUTH SAN FRANCISCO, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASD

      4/25/25 1:10:00 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

      In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), into a registrational studyCompany remains confident in continuing to pursue evorpacept in multiple clinical trials, based on the different mechanism of evorpacept in combination with anti-cancer antibodies, as evidenced by durable clinical response and consistent safety data in prior clinical trials SOUTH SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat ca

      4/25/25 9:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate

      ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology's proprietary linker-payload platformALX2004, the company's first ADC, was fully designed and developed in-house by ALX Oncology scientistsCompany expects to initiate Phase 1 clinical trials of ALX2004 in mid-2025, with initial safety data available in 1H 2026 SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives,

      4/7/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, March 8, 2025 /PRNewswire/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual cases by 2030 and a staggering 75% increase by 2050. According to the World Health Organization (WHO), breast cancer cases are projected to rise by nearly 40% by 2050. Despite the concerning trends in cancer incidence, 2025 has seen key advancements from biotech companies at the forefront of oncology research, with Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Exelixis, Inc. (NASDAQ:EXEL), Cardiff Oncology, Inc. (NASDAQ:CRDF

      3/8/25 7:33:00 AM ET
      $ALXO
      $CRDF
      $EXEL
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      – Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI – Presented Phase 1b/2 data demonstrating evorpacept in combination with zanidatamab generates promising anti-tumor activity in advanced breast cancer at SABCS 2024 – Announced focused development plan during R&D Day, including introduction of clinical trials evaluating evorpacept plus anti-cancer antibodies in breast and colorectal cancers and novel EGFR-targeted antibody-drug conjugate (ADC) clinical candidate ALX2004 – Strategic prioritization and resource

      3/6/25 4:01:00 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by SVP, FINANCE AND CAO Pinto Shelly

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      4/15/25 4:29:19 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Sandler Alan B.

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      4/15/25 4:19:34 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Shantharam Harish

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      4/15/25 4:16:28 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Lettmann Jason

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      4/15/25 4:14:02 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, FINANCE AND CAO Pinto Shelly was granted 3,000 shares, increasing direct ownership by 3% to 90,352 units (SEC Form 4)

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      3/18/25 4:45:00 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Lettmann Jason was granted 42,000 shares, increasing direct ownership by 25% to 212,270 units (SEC Form 4)

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      3/18/25 4:41:30 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, FINANCE AND CAO Pinto Shelly sold $633 worth of shares (550 units at $1.15), decreasing direct ownership by 0.63% to 87,352 units (SEC Form 4)

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      2/21/25 4:25:30 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT & CSO Pons Jaume sold $1,525 worth of shares (1,326 units at $1.15), decreasing direct ownership by 0.23% to 579,388 units (SEC Form 4)

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      2/21/25 4:23:12 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Lettmann Jason sold $2,483 worth of shares (2,159 units at $1.15), decreasing direct ownership by 1% to 170,270 units (SEC Form 4)

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      2/21/25 4:20:19 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hemrajani Rekha

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      1/23/25 6:32:49 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ALX Oncology Holdings Inc. Leadership Updates

    Live Leadership Updates

    See more
    • ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

      Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operationsDr. Klencke is a seasoned clinical leader in oncology drug development with more than 20 years of industry experienceDr. Takimoto brings a distinguished track record in oncology and drug development with 17 years of industry experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced the appointmen

      1/22/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, announced today the appointment of Alan Sandler, M.D., as Chief Medical Officer. "Dr. Sandler's breadth of experience and demonstrated leadership capabilities across oncology and drug development, as well as his in-depth knowledge of ALX Oncology while he was a member of our Board, will be instrumental in helping us achieve our near- and longer-term objectives," said Jason Lettmann, Chief Executive Officer at

      11/14/24 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. "Our team continues to make significant progress in the advancement of our evorpacept development pipeline across multiple oncology indications," said Jason Lettmann, Chief Executive Officer of ALX Oncology. "Data readouts across our Phase 1 and 2 clinical trials highlight the potential of evorpacept as a disruptive therapy in combination with anti

      8/8/24 4:05:00 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

      - Dr. Sandler brings more than 30 years of experience and leadership in oncology and drug development - - Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., will leave board to focus on ALX leadership responsibilities as Company's clinical program advances - SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced today the appointment of Alan Sandler, M.D., to its Board of Directors effective August 5, 2024. Dr. Sandler is a distinguished leader in oncology and drug development with over 30 years of e

      8/6/24 4:01:00 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

      SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. "We entered the quarter with a great deal of momentum having achieved a key validating development milestone for our platform asset evorpacept in Q4 2023 by reporting positive results in a prespecified randomized interim analysis of ASPEN-06's Phase 2 clinical trial in advanced HER2-positive gastric/GEJ cancer, becoming the first CD47 blocker to demon

      5/9/24 4:00:00 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Appoints Allison Dillon as Chief Business Officer

      SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer ("CBO"). "We are excited to welcome Allison to our leadership team in the midst of this promising growth period for our Company," said Jason Lettmann, Chief Executive Officer of ALX Oncology. "For over 15 years, Allison has worked to develop and deliver novel oncology products to patients with cancer. With multiple clinical study readouts over the next 12 months, Allison's

      5/7/24 9:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Appoints Scott Garland to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ:ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Scott Garland to its Board of Directors (the "Board") effective November 29, 2022. With more than 30 years of biopharmaceutical industry knowledge, Mr. Garland brings deep commercial and executive leadership experience. "Scott is a biopharmaceutical industry leader who brings broad commercial, portfolio management, and leadership experience to the Board," said Corey Goodman, Ph.D., Executive Chairman of ALX Oncology. "His strategic ex

      11/29/22 7:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

      SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ:ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended March 31, 2022 and provided clinical development and operational highlights. "Throughout the first quarter, we continued to realize significant progress advancing our lead program, evorpacept, through multiple clinical trials," said Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology. "Our highlights include dosing the first patient in ASPEN-06, our Phase 2/3 study testing evorpac

      5/9/22 4:01:00 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ:ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Itziar Canamasas, Ph.D., to its Board of Directors (the "Board") effective April 11, 2022. With more than 20 years of biopharmaceutical industry experience, Dr. Canamasas brings expertise in driving business growth and operational excellence. "We are excited to welcome Dr. Canamasas to our Board during an important time in ALX Oncology's continued evolution," said Corey Goodman, Ph.D., Executive Chairman of ALX Oncology. "Dr. Canamas

      4/12/22 7:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

      BURLINGAME, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ:ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended March 31, 2021 and provided recent clinical development and operational highlights. "Having achieved important milestones in the first quarter of 2021, we look forward to what we expect will be another exciting year of substantial progress for our lead candidate, ALX148, as we prepare to initiate several clinical trials in combination with other agents in a variety of indications, as well as multiple anticipated data r

      5/17/21 4:05:00 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ALX Oncology Holdings Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hemrajani Rekha bought $46,404 worth of shares (30,000 units at $1.55), increasing direct ownership by 1,000% to 33,000 units (SEC Form 4)

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      12/4/24 4:17:28 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)

      4/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      6/24/24 9:00:55 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      6/17/24 7:29:53 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lettmann Jason bought $49,771 worth of shares (4,400 units at $11.31), increasing direct ownership by 3% to 171,620 units (SEC Form 4)

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      3/18/24 4:06:28 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ALX Oncology Holdings Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

      SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      11/14/24 7:22:54 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

      SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      11/14/24 6:58:27 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

      SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      11/14/24 3:02:41 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

      SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      11/12/24 9:50:12 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

      SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      10/10/24 4:14:37 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ALX Oncology Holdings Inc.

      SC 13G - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      8/22/24 4:00:18 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ALX Oncology Holdings Inc.

      SC 13G - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      8/13/24 4:17:23 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ALX Oncology Holdings Inc. (Amendment)

      SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      2/14/24 7:45:10 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ALX Oncology Holdings Inc. (Amendment)

      SC 13D/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      2/14/24 7:28:02 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ALX Oncology Holdings Inc. (Amendment)

      SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      2/14/24 4:26:23 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ALX Oncology Holdings Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ALX Oncology upgraded by Jefferies with a new price target

      Jefferies upgraded ALX Oncology from Hold to Buy and set a new price target of $3.00 from $2.00 previously

      3/6/25 7:17:16 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology downgraded by Jefferies with a new price target

      Jefferies downgraded ALX Oncology from Buy to Hold and set a new price target of $2.00 from $12.00 previously

      12/19/24 7:28:17 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology downgraded by Stifel with a new price target

      Stifel downgraded ALX Oncology from Buy to Hold and set a new price target of $14.00 from $10.00 previously

      3/8/24 7:21:35 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology upgraded by Jefferies with a new price target

      Jefferies upgraded ALX Oncology from Hold to Buy and set a new price target of $18.00 from $8.00 previously

      12/8/23 7:31:40 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel reiterated coverage on ALX Oncology Holdings with a new price target

      Stifel reiterated coverage of ALX Oncology Holdings with a rating of Buy and set a new price target of $36.00 from $60.00 previously

      3/1/22 10:33:04 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Holdings downgraded by Jefferies with a new price target

      Jefferies downgraded ALX Oncology Holdings from Buy to Hold and set a new price target of $25.00 from $65.00 previously

      12/22/21 5:34:20 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on ALX Oncology Holdings with a new price target

      Stifel initiated coverage of ALX Oncology Holdings with a rating of Buy and set a new price target of $106.00

      9/30/21 4:47:37 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse resumed coverage on ALX Oncology with a new price target

      Credit Suisse resumed coverage of ALX Oncology with a rating of Outperform and set a new price target of $98.00

      5/5/21 6:42:06 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse resumed coverage on ALX Oncology with a new price target

      Credit Suisse resumed coverage of ALX Oncology with a rating of Outperform and set a new price target of $98.00

      4/26/21 8:50:51 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on ALX Oncology Holdings with a new price target

      UBS initiated coverage of ALX Oncology Holdings with a rating of Buy and set a new price target of $96.00

      4/6/21 9:29:12 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ALX Oncology Holdings Inc. Financials

    Live finance-specific insights

    See more
    • ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

      SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX OncologyALX Oncology (NASDAQ:ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives. ALX Oncology's lea

      5/2/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

      SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open.  The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX OncologyALX Oncology (NASDAQ:ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives.

      2/27/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

      Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized trialGreatest benefit observed among patients with confirmed HER2-positive cancer, as demonstrated by either fresh biopsy or ctDNA HER2-expression, with confirmed ORR of 48.9% and mDOR of 15.7 months vs. 24.5% ORR and mDOR of 9.1 months in the control group, and a PFS Hazard Ratio of 0.64Company to host conference call and investor webcast today at 1:00 PM PT/4:00 PM ET SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology

      1/23/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

      Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive gastric cancer SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that the company will host a virtual event on Thursday, January 23, at 1:00 p.m. PT/4:00 p.m. ET to discuss updated data from the ASPEN-06 Phase 2 clinical trial evaluating the company's investigational CD47-blocker evorpacept in patients with previou

      1/21/25 5:00:00 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

      Evorpacept is the first CD47 blocker to show durable clinical benefit and a well-tolerated safety profile in a prospective randomized trial Evorpacept combination achieved a confirmed overall response rate (ORR) of 40.3% compared to 26.6% for the control arm and demonstrated a median duration of response of 15.7 months compared to 7.6 months in the full trial populationIn the pre-specified population of patients with fresh HER2-positive biopsies, evorpacept combination showed the greatest benefit with ORR of 54.8% vs. 23.1% in the control, suggesting HER2-expression strongly correlates with evorpacept efficacy and validating its mechanism of actionCompany to host conference call and

      7/31/24 4:01:00 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

      Conference Call and Webcast Today at 4:30 PM EDT SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-positive gastric cancer. To access the live conference call, please dial (800) 715-9871 (U.S./Canada) or +44.800.260.6466 (internationally), Conference ID 9637001. To access the live a

      7/31/24 5:30:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

      Evorpacept in combination with PADCEV®, an approved antibody-drug conjugate ("ADC"), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on Friday, June 7, 2024, at 1:00 PM ET SOUTH SAN FRANCISCO, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today presented data from its Phase 1 ASPEN-07 clinical trial in a poster presentation (abstract #4575) at the 2024 American Society of Cancer Oncology ("ASCO")

      6/2/24 10:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

      -- Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors -- Interim efficacy results showed the confirmed overall response rate for evorpacept combination treatment was 52% compared to 22% for control treatment -- Company to host conference call and webcast today at 8:00 AM EDT SOUTH SAN FRANCISCO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial, a randomized multi-center international stu

      10/3/23 6:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

      SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the hosting of an investor call and webcast on Tuesday, October 3rd at 8:00 AM EDT to share interim Phase 2 ASPEN-06 clinical trial results of evorpacept for the treatment of advanced HER2-positive gastric cancer. To access the live conference call, please dial (800) 715-9871 (U.S./Canada) or +44.800.260.6466 (internationally), Conference ID 7797378. To access the live and archived webcast of the conference call, please visit the News & Event

      10/2/23 4:05:00 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia

      -- Antileukemic activity demonstrated in patients with both relapsed/refractory and newly diagnosed AML-- No evorpacept-related cytopenias observed and no maximum tolerated dose identified in combination with azacitidine and venetoclax -- ALX Oncology to Host Conference Call on December 13th at 7:30 a.m. EST SOUTH SAN FRANCISCO, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ:ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the presentation of clinical data from the Phase 1a dose escalation part of the ASPEN-05 trial evaluating evorpacept in combination with azacitidi

      12/12/22 10:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care